other · 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1) - Fig 3
Tarik Asselah (717526), Christophe Moreno (798309), Christoph Sarrazin (48298), Michael Gschwantler (3151779), Graham R. Foster (2577061), Antonio Craxí (3151770), Peter Buggisch (587274), Robert Ryan (3151776)
<p>Percentage of <b>[A]</b> all patients, and <b>[B]</b> patients receiving 12 weeks of treatment who achieved SVR12, according...
0 citationsDOI: https://doi.org/10.1371/journal.pone.0158526.g003Open access